Trial ended March 2021.
Canine Osteosarcoma with Metastasis to the Lungs
Pharmacological Tumor Microenvironment Modification with 3-Drug Combination in Canine Metastatic Osteosarcoma
Purpose of the study:
- To evaluate the anti-tumor effects of a 3-drug combination of toceranib (Palladia), losartan, and propranolol in dogs with metastatic osteosarcoma
Primary Eligibility Criteria:
- Dogs that have had surgery to remove their primary tumor and a confirmed diagnosis of osteosarcoma with measureable metastatic disease in the lungs on chest X-rays
- Adequate blood work
- Two-week washout from chemotherapy or radiation therapy; no concurrent treatment with any immunosuppressive drugs; no prior immunotherapy for OSA
- No metastatic disease anywhere besides the lungs
- No pre-existing allergic airway disease or a significantly low heart rate
- Pets must come to CSU for all visits related to the clinical trial
- Dogs will be treated with oral losartan and propranolol to be given twice daily and oral Palladia given once every other day.
- Rechecks will be required every 2 weeks following the start of treatment for the 1st 3 months, and every 4 weeks thereafter if tumors are stable or better
- At the week 2 visit, your dog will need to stay in the hospital all day for serial blood collections following propranolol administration
- Chest x-rays will be rechecked every 8 weeks while on study
- You are responsible for the initial testing to determine study eligibility and any other tests recommended by your pet’s oncologist
- You are responsible for the costs of the exam fee at each study appointment
- You are expected to make and keep all appointments associated with the study
- You must be comfortable administering oral medications at home
- The oral immune therapy drugs (Palladia, losartan and propranolol) will be provided at no cost for the 1st 6 months of treatment.
- All recheck appointment charges other than the exam fee during the initial 6 months of the study will be covered by the study, including blood work and blood pressure monitoring.
- The study will also cover the cost of the recheck chest x-rays performed every 8 weeks
for the first year of the study to assess your pet’s response to therapy.
- After the initial 6 months of the study, you are responsible for all costs related to study
participation other than chest x-rays.